A5058921635- Systemic Lupus Erythematosus Research
- Platelet Disorders and Treatments
- Gastric Cancer Management and Outcomes
- Cell Adhesion Molecules Research
- Monoclonal and Polyclonal Antibodies Research
- Helicobacter pylori-related gastroenterology studies
- Systemic Sclerosis and Related Diseases
- Blood disorders and treatments
- Eosinophilic Esophagitis
- Colorectal Cancer Surgical Treatments
- Gastrointestinal disorders and treatments
- Diverticular Disease and Complications
- Metastasis and carcinoma case studies
- Renal Diseases and Glomerulopathies
- Gastroesophageal reflux and treatments
- Colorectal Cancer Screening and Detection
- Esophageal Cancer Research and Treatment
- Immune Response and Inflammation
- Pregnancy and Medication Impact
- Biosimilars and Bioanalytical Methods
- Neutrophil, Myeloperoxidase and Oxidative Mechanisms
- Reproductive System and Pregnancy
- Esophageal and GI Pathology
- COVID-19 Clinical Research Studies
- Veterinary medicine and infectious diseases
IRCCS Istituto Auxologico Italiano
2014-2025
Istituti di Ricovero e Cura a Carattere Scientifico
2014-2025
University of Milan
2004-2023
Aziende Socio Sanitarie Territoriale Lodi
2023
Universitat Politècnica de Catalunya
2020
FC Barcelona
2020
ASL Roma
2020
Ospedale San Giuseppe
2018
University of Florence
2014
Sapienza University of Rome
2000-2002
Critically ill patients with coronavirus disease 2019 (COVID-19) have a profound hypercoagulable state and often develop coagulopathy which leads to organ failure death. Because of prolonged activated partial-thromboplastin time (aPTT), relationship anti-phospholipid antibodies (aPLs) has been proposed, but results are controversial. Functional assays for aPL (i.e., lupus anticoagulant) can be influenced by concomitant anticoagulation and/or high levels C reactive protein. The presence...
Objective It has been suggested that only antibodies against domain 1 (D1) of β 2 ‐glycoprotein I (β GPI) are pathogenic and diagnostic. The role other GPI domains is still debated. This study was undertaken to evaluate the clinical relevance specificity profiling anti‐β IgG in antiphospholipid syndrome (APS) patients control groups with systemic autoimmune rheumatic diseases asymptomatic antibody (aPL) carriers. Methods We evaluated 159 subjects persistently positive, medium or high‐titer...
Clinical studies have reported different diagnostic/predictive values of antibodies to domain 1 or 4/5 β2glycoproteinI in terms risk thrombosis and pregnancy complications patients with antiphospholipid syndrome. To obtain direct evidence for the pathogenic role anti-domain antibodies, we analyzed vivo pro-coagulant effect two groups 5 sera IgG each reacting selectively lipopolysaccharide (LPS)-treated rats. Antibody-induced thrombus formation mesenteric vessels was followed by intravital...
Abstract Objectives The Certified Reference Material (CRM) ERM ® -DA477/IFCC is a new polyclonal IgG anti-beta2-glycoprotein I (anti-β2GPI) material for the harmonization of laboratory diagnosis antiphospholipid syndrome (APS). We evaluated CRM’s ability to represent heterogeneity APS patient anti-β2GPI antibodies and calibrate methods. Methods characterized CRM its reactivity against domain-1, using QUANTA Flash β2GPI-domain-1 assay, domains-4-5 β2GPI, single-domain-deleted β2GPI molecules...
Background. Anaemia is one of the major clinical characteristics patients with chronic renal failure, and has a considerable effect on morbidity mortality. Adequate dialysis paramount importance in correcting anaemia by removing small medium‐sized molecules, which may inhibit erythropoiesis. However, high‐molecular‐weight inhibitors cleared only means highly porous membranes have also been found uraemic serum it claimed from uncontrolled studies that high‐flux could improve haemodialysis patients.
Antiphospholipid antibodies (aPL) can be detected in asymptomatic carriers and infectious patients. The aim was to investigate whether a novel line immunoassay (LIA) differentiates between antiphospholipid syndrome (APS) aPL+ or patients with diseases (infectious controls (IDC)).Sixty-one APS (56 primary, 22/56 obstetric events only, 5 secondary), 146 including 24 73 IDC were tested on hydrophobic solid phase coated cardiolipin (CL), phosphatic acid, phosphatidylcholine,...
Abstract Background Critically ill patients with coronavirus disease 2019 (COVID-19) have a profound hypercoagulable state and often develop coagulopathy which leads to organ failure death. Because of prolonged activated partial-thromboplastin time (aPTT), relationship anti-phospholipid antibodies (aPL) has been proposed, but results are controversial. Functional assays for aPL (i.e., lupus anticoagulant) can be influenced by concomitant anticoagulation and/or high levels C reactive protein....